It’s official. The FDA will convene this Tuesday (13) to discuss and come to a decision on the fate of GSK’s Avandia. I guess you could literally call this agent a wonder drug — as its continued availability in the Pharma marketplace in spite of hundreds of class action lawsuits, multiple studies stretching back to at least 2005 documenting a clear association with an increase in heart attack risk, and copious physician calls for its withdrawal — continues to amaze healthcare policy watchers.

For the first time it appears that the handwringing on both sides of this hotly debated drug (Pharma/GSK vs. medical critics) appears to be taking on an overtly political tone, as even within the government agency itself, there is a deep devision over just how this entire case should be handled. The hoopla surrounding the removal of Vioxx and Bextra (anti-inflammatories with similarly documented cardiac risks) was never this contentious. Even U.S. senators have weighed in on the issue.^[1] What will the fate of this drug be? Tighter restrictions on its use, or complete removal from the pharma marketplace? Perhaps the answer says as much about the FDA as it does about GSK. | LINK

1. Sens. Baucus and Grassley published a report questioning the FDA’s rationale for keeping the drug available while GSK knew about the drug’s risks. [↩]

Related Posts Within Doctor Pundit:

1. FDA Considers Ending Troubled GSK Drug’s Involvement in Safety Study Add yet another blow to GSK’s once-blockbuster diabetes drug, Avandia...
2. Diabetes Drug Once Again under Scrutiny A couple of weeks before the FDA meets to discuss...
3. Report: Pharma Company Covered Up Known Cardiovascular Risks of Drug GSK (then known as SmithKline Beecham) knew in a 1999...
4. FDA: Avandia Stays on Market The vote is 20-12 against withdrawing GSK’s troubled drug Avandia...
5. Top Ten DP Posts for 2010 (Nos. 4-2) Two thousand ten brought the realization of Obama’s labors into...